Core Insights - The recent market correction has created buying opportunities for investors in high-growth companies that are addressing real-world problems, with many stocks trading at 30-day lows despite strong operational progress [1][2]. Group 1: Symbotic (SYM) - Symbotic develops AI-enabled robotic systems for automating high-volume warehouses, reporting Q3 2025 revenue of $592 million, a 26% year-over-year increase, and adjusted EBITDA rising to $45 million from $3 million [3][5]. - The company has a significant backlog of approximately $22.4 billion, primarily from long-term contracts with Walmart and GreenBox, providing multiyear revenue visibility [5][6]. - Despite a 14% decline in shares over the past 30 days, the company is positioned for growth with a substantial contracted workload ahead [6]. Group 2: AST SpaceMobile (ASTS) - AST SpaceMobile aims to create the first space-based cellular broadband network compatible with standard smartphones, achieving Q3 2025 revenue of $14.7 million, up from $1.1 million a year ago, driven by government contracts [7][9]. - The company has over $1 billion in contracted revenue commitments and has signed agreements with more than 50 mobile network operators, serving nearly 3 billion subscribers [9][10]. - Execution and launch timelines are critical factors, with recent revenue misses contributing to stock volatility, but the current weakness offers a favorable entry point for investors [10]. Group 3: SS Innovations International (SSII) - SS Innovations has installed over 100 SSi Mantra surgical robotic systems and completed over 5,000 procedures, indicating a transition from concept to scale [11][13]. - The company plans to file a 510(k) premarket notification in Q4 2025 for multiple surgical indications, which could expedite FDA clearance [13][14]. - This small-cap stock has shown less volatility compared to others, with only a 5% decline over the past 30 days as investors await regulatory updates [15].

Core Insights - SS Innovations has successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), marking a historic milestone in robotic telesurgery [1][4][5] Group 1: Product Overview - The SSi Mantra Tele Surgeon Console is a compact, self-contained, chair-based system designed for telesurgery, allowing operations from various locations, including physician offices [2][4] - The TSC features 3D visualization, magnetic sensor controls, and a smaller footprint compared to traditional operating room setups, enhancing flexibility for surgical experts [7][9] Group 2: Surgical Achievement - Dr. Sudhir Srivastava performed a robotic-assisted coronary artery bypass surgery remotely from New Delhi on a patient located 185 miles away in Jaipur, demonstrating the TSC's capability to extend surgical expertise globally [3][5] Group 3: Company Vision and Future Plans - SS Innovations aims to make robotic surgery affordable and accessible to a broader global population, with plans to expand its presence and technological offerings [8] - The company has refined the TSC since its initial showcase at the Society of Robotic Surgery Meeting in June 2024, indicating ongoing innovation and development [5]

Compact New Console Facilitates Performance of Telesurgeries from a Wide Range of Locations, including Physicians’ OfficesFORT LAUDERDALE, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful completion of the first telesurgery performed with the Company’s SSi Mant ...

Revenue Growth - Revenue increased 192.5% year over year to $12.8 million from $4.4 million in Q3 2024[5] - Total revenue for the first nine months of 2025 increased 123.0% to $28.0 million from $12.5 million in the first nine months of 2024[5] - Total revenue for Q3 2025 reached $12,829,349, a significant increase of 192% compared to $4,386,516 in Q3 2024[20] - For the nine months ended September 30, 2025, total revenue was $27,950,264, an increase of 123% from $12,533,335 in the same period of 2024[21] Gross Profit and Margin - Gross profit rose 166.0% to $6.2 million from $2.3 million in Q3 2024[5] - Gross profit for Q3 2025 was $6,164,936, compared to $2,317,407 in Q3 2024, reflecting a gross margin improvement[20] System Installations and Surgeries - SSi Mantra surgical robotic system installations totaled 27, up 350.0% from 6 installations in Q3 2024[5] - SSi Mantra installations for the first nine months of 2025 totaled 63, up 152.0% from 25 installations in the first nine months of 2024[10] - Cumulative surgeries reached 6,057, including 56 telesurgeries and 319 cardiac procedures[5] Net Loss and Financial Performance - Net loss of $3.7 million, or $(0.02) per diluted share, compared to a net loss of $3.2 million, or $(0.02) per diluted share, in Q3 2024[5] - The net loss for Q3 2025 was $3,717,964, compared to a net loss of $3,245,483 in Q3 2024, indicating a worsening of financial performance despite revenue growth[20] Cash and Liquidity - Cash and cash equivalents totaled $5.7 million, excluding restricted cash[5] - Cash and cash equivalents at the end of Q3 2025 were $12,039,247, up from $6,152,262 at the end of Q3 2024, showing improved liquidity[23] Operating and Research Expenses - Operating expenses for the nine months ended September 30, 2025, totaled $20,626,239, slightly down from $21,620,651 in the same period of 2024[21] - Research and development expenses for the nine months ended September 30, 2025, were $2,295,014, an increase from $1,729,834 in the same period of 2024[21] Foreign Currency Impact - The company reported a foreign currency translation loss of $480,822 in Q3 2025, compared to a loss of $59,087 in Q3 2024[20] Future Plans - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025[6] - The company aims for European Union CE marking certification in the first half of 2026[6] Share Dilution - The weighted average diluted shares increased to 202,856,501 in Q3 2025 from 181,885,269 in Q3 2024, reflecting dilution from equity financing[20]

Financial Performance - Total revenue for the three months ended September 30, 2025, was $12,829,349, a significant increase from $4,386,516 for the same period in 2024, representing a growth of approximately 192%[202]. - Gross profit for the three months ended September 30, 2025, was $6,164,936, compared to $2,317,407 in the same period of 2024, reflecting an increase in gross profit margin due to lower raw material prices[203]. - For the nine months ended September 30, 2025, total revenue was $27,950,264, compared to $12,533,335 for the same period in 2024, marking an increase of approximately 123%[212]. - The net loss for the three months ended September 30, 2025, was $3,717,964, compared to a net loss of $3,245,483 for the same period in 2024, despite an increase in gross profit[211]. - The Company reported a net loss of $17,227,806 for the nine months ended September 30, 2024, with non-cash adjustments of $13,528,234[232]. Market Activity - The company sold 28 surgical robotic systems in the three months ended September 30, 2025, and 55 systems in the nine months ended September 30, 2025, indicating a growing market presence[197]. Expenses - Research and development expenses for the three months ended September 30, 2025, were $786,319, up from $442,839 in the same period of 2024, reflecting ongoing investment in product enhancements[204]. - Selling, general and administrative expenses increased to $4,821,552 for the three months ended September 30, 2025, compared to $2,508,479 in the same period of 2024, primarily due to higher legal and underwriting fees[207]. Assets and Cash Flow - Total assets as of September 30, 2025, were $69,577,027, up from $42,385,213 as of December 31, 2024, indicating strong growth in the company's financial position[200]. - Cash at the end of the year on September 30, 2025, was $12,039,247, compared to $6,152,262 at the end of the previous year[230]. - In the nine months ended September 30, 2025, the net cash used in operating activities was $17,023,417, resulting from a net loss of $9,656,008[230]. - The Company had a net cash used in investing activities of $1,944,527 for the purchase of property and equipment during the nine months ended September 30, 2025[234]. Financing Activities - The Company raised $24,793,391 from financing activities during the nine months ended September 30, 2025, primarily from the issuance of convertible notes[235]. - The Company sold $2,450,000 in principal amount of 7% Convertible One-Year Promissory Notes, with a conversion price of $4.45 per share[225]. - As of September 30, 2025, all $30,000,000 in principal amount of One-Year Notes were converted into 21,858,368 shares of common stock at a conversion price of $1.38 per share[228]. - The net cash provided by financing activities in the nine months ended September 30, 2024, was $6,014,946, including proceeds from convertible notes and promissory notes[236]. - The Company raised $2,000,000 from Sushruta through the issuance of two One-Year 7% Promissory Notes in April 2024[226]. Taxation and Funding Concerns - The company incurred an income tax expense of $1,847,059 for the three months ended September 30, 2025, due to the recognition of taxable profits in its Indian operations for the first time[210]. - The Company does not have any committed sources of funding, raising substantial doubt about its ability to continue as a going concern[229]. - The Company plans to raise additional capital through private or public offerings to support its expansion and R&D efforts, highlighting the need for ongoing funding[201].

Core Insights - SS Innovations International, Inc. reported a significant revenue increase of 192.5% year-over-year, reaching $12.8 million in Q3 2025, primarily driven by higher sales of the SSi Mantra 3 surgical robotic system [1][6][11] Financial Performance - Q3 2025 revenue rose to $12.8 million from $4.4 million in Q3 2024, with a gross profit increase of 166.0% to $6.2 million [6][11] - Gross margin for Q3 2025 was 48.1%, down from 52.8% in Q3 2024 [6] - The net loss for Q3 2025 was $3.7 million, consistent with the net loss of $3.2 million in Q3 2024 [6][11] - For the first nine months of 2025, total revenue increased by 123.0% to $28.0 million compared to $12.5 million in the same period of 2024 [6][8] - Cumulative surgeries performed using the SSi Mantra reached 6,057, including 56 telesurgeries and 319 cardiac procedures [6][12] Business Highlights - The number of SSi Mantra installations in Q3 2025 totaled 27, a 350.0% increase from 6 installations in Q3 2024 [6][11] - The cumulative installed base of SSi Mantra systems reached 127 across seven countries [6][11] - The company has received regulatory approval for the SSi Mantra in seven countries and is preparing to enter the U.S. and European Union markets [4][12] Upcoming Developments - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025 and aims for CE marking certification in the EU in the first half of 2026 [4][12] - SS Innovations is scheduled to participate in investor conferences in November 2025, providing opportunities for management to engage with investors [9][10]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [2][5] - The company will participate in upcoming investor conferences, including the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference [3][4] Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with cost-effective surgical robotic solutions [5] - The company's product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various surgical procedures, including robotic cardiac surgery [5] Product Performance - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals having installed the system [6] - Over 6,000 surgical procedures have been performed using the SSi Mantra, including 60 telesurgeries and 310 cardiac procedures [6] Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time image display [7] - It utilizes over 40 different types of robotic endo-surgical instruments and has been clinically validated in India for more than 100 different types of surgical procedures [8]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to enhance the accessibility and affordability of robotic surgery globally [4][5]. Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with its advanced and cost-effective surgical robotic solutions [4]. - The company’s product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which cater to various surgical procedures, including robotic cardiac surgery [4]. Recent Developments - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals utilizing the system [5]. - Over 6,000 surgical procedures have been performed using the SSi Mantra, which includes 60 telesurgeries and 310 cardiac procedures [5]. Upcoming Events - Dr. Sudhir Srivastava and Dr. Vishwa Srivastava will participate in the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025 [2][3]. - The Stifel conference will feature a group presentation at 4:40 p.m. Eastern Time, with a live webcast available on the company’s website [3]. Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system equipped with advanced technology features, including 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time imaging capability [6]. - It supports over 40 different types of robotic endo-surgical instruments, validated in more than 100 types of surgical procedures in India [6].

Core Insights - SS Innovations International, Inc. has successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital, marking a significant milestone in its regulatory process [1][2] - The company plans to submit a 510(k) premarket notification to the FDA in the fourth quarter of 2025, aiming for potential market clearance in the first half of 2026 [1][3] - The SSi Mantra has a cumulative installed base of 125 systems across six countries, with over 6,000 surgical procedures performed to date [4] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery more affordable and accessible globally [5] - The SSi Mantra system features a modular design with advanced technology, including multiple robotic arms and a 3D 4K monitor, supporting various surgical specialties [6] Regulatory Pathway - The company has shifted from a De Novo request to a 510(k) regulatory pathway, which is expected to provide speed and cost advantages in the approval process [4] - RQM+, a MedTech-focused CRO, has been engaged to assist with the 510(k) submission [2]

Company Overview - SS Innovations International, Inc. (NASDAQ:SSII) is focused on advancing affordable surgical robotics with its flagship SSi Mantra system, which provides a cost-efficient alternative to established platforms like Intuitive Surgical's da Vinci [2] - The SSi Mantra system has received approval in seven countries, including India, Indonesia, and the Philippines, and the company is seeking regulatory approval in the U.S. and Europe to expand its market presence [2] Financial Performance - In Q2 2025, SS Innovations International, Inc. reported a revenue increase of 121.8% to $10 million, with gross profit more than tripling year-over-year [4] - The installations of the SSi Mantra system grew by 130% year-over-year, resulting in a total installed base of 105 systems that have performed 4,657 surgeries as of June 30, 2025 [4] Leadership Changes - Naveen Kumar Amar was appointed as Chief Financial Officer in September 2025, bringing extensive international finance experience as the company prepares for increased sales and regulatory submissions [3] Technological Achievements - The company achieved a significant milestone by performing the world's first intercontinental robotic cardiac telesurgery in July 2025, showcasing its advanced technological capabilities [4]